Welcome to Multibagg AI
Log in to access personalized features
Portfolio
Alerts
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Discovery themes featuring this stockBearish
2
Neutral
8
Bullish
4
Bearish
13
Neutral
8
Bullish
25
Bearish
11
Neutral
0
Bullish
21
Bearish
2
Neutral
8
Bullish
4
Bearish
2
Neutral
8
Bullish
4
Bearish
11
Neutral
0
Bullish
21
Bearish
11
Neutral
0
Bullish
21
Bearish
11
Neutral
0
Bullish
21
Fermenta Biotech Ltd (FERMENTA) is currently trading at 489.40 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Fermenta Biotech Limited manufactures and supplies scientifically-validated nutritional ingredients, APIs, enzymes, and green-chemistry solutions to global pharmaceutical, nutraceutical, food, veterinary and animal feed customers, operating manufacturing sites across India and a German toll manufacturing collaboration, supported by an R&D hub and multiple global regulatory certifications. The company posted consolidated 9M FY26 revenue of INR 421.2 crore, up 25% year‑on‑year, driven by a 51% increase in Human Vitamin D3 and a 46% rise in Animal Nutrition volumes, while Q3 showed sequential revenue improvement despite YoY moderation linked to a large one-off real estate income in the prior year. Fermenta demonstrates strong operating leverage: raw-materials reduced to 38% of revenue from 53% in FY24, manufacturing expense fell to 11% in 9M FY26, and finance costs declined to 2%, indicating procurement efficiency, capacity utilisation gains, and deleveraging that position Fermenta for margin expansion as volumes continue to scale. R&D and product differentiation are tangible growth drivers: Fermenta holds patents including spray-dried 100,000 IU/g Vitamin D3 with CEP certification, plant-based VITADEE™ Green, and enzyme/IP commercialization plans such as Calcefediol and Penmox technology, giving Fermenta Biotech Limited premium product positioning for regulated European and pharmaceutical markets. Customer diversification is a strength: the largest customer is only 7% of revenue and the top 10 customers account for 43%, while geographic mix is shifting toward Europe (now 32%), reflecting Fermenta’s ability to expand institutional and regulated-market sales beyond domestic reliance.
Over the past 52 weeks, Fermenta Biotech Ltd has traded between a low of ₹256.40 and a high of ₹579.65. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Fermenta Biotech Ltd has a market capitalization of approximately 1,419.02. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Fermenta Biotech Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 24.39 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 1,419.02 Cr, Fermenta Biotech Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Fermenta Biotech Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Fermenta Biotech Ltd is 24.39. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
FSSAI approved Fermenta Biotech’s plant-based Vitamin D3 (Cholecalciferol) product, VITADEE Green®, allowing it to be marketed for food and health supplement use in India.
Discovery themes featuring this stock
Fermenta Biotech Limited manufactures and supplies scientifically-validated nutritional ingredients, APIs, enzymes, and green-chemistry solutions to global pharmaceutical, nutraceutical, food, veterinary and animal feed customers, operating manufacturing sites across India and a German toll manufacturing collaboration, supported by an R&D hub and multiple global regulatory certifications.
The company posted consolidated 9M FY26 revenue of INR 421.2 crore, up 25% year‑on‑year, driven by a 51% increase in Human Vitamin D3 and a 46% rise in Animal Nutrition volumes, while Q3 showed sequential revenue improvement despite YoY moderation linked to a large one-off real estate income in the prior year.
Fermenta demonstrates strong operating leverage: raw-materials reduced to 38% of revenue from 53% in FY24, manufacturing expense fell to 11% in 9M FY26, and finance costs declined to 2%, indicating procurement efficiency, capacity utilisation gains, and deleveraging that position Fermenta for margin expansion as volumes continue to scale.
R&D and product differentiation are tangible growth drivers: Fermenta holds patents including spray-dried 100,000 IU/g Vitamin D3 with CEP certification, plant-based VITADEE™ Green, and enzyme/IP commercialization plans such as Calcefediol and Penmox technology, giving Fermenta Biotech Limited premium product positioning for regulated European and pharmaceutical markets.
Customer diversification is a strength: the largest customer is only 7% of revenue and the top 10 customers account for 43%, while geographic mix is shifting toward Europe (now 32%), reflecting Fermenta’s ability to expand institutional and regulated-market sales beyond domestic reliance.
Pharmaceuticals & Biotechnology
Pharmaceuticals
1,419 Cr
Low Risk
24.4
37.7
-0.5
3.5
579.65
256.40
Sales CAGR
Profit CAGR
ROE
ROCE
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
237.00 | 1,571 Cr | 34.55 | 5.69 | 1.71 | 15.60 | 20.59 | 14.36 | ||
642.95 | 1,542 Cr | 35.17 | 5.60 | 0.16 | 15.92 | 21.28 | 13.63 | ||
503.05 | 1,442 Cr | 26.71 | 3.89 | 0.98 | 17.42 | 23.31 | 10.61 | ||
482.15 | 1,419 Cr | 24.39 | 3.49 | 0.76 | 17.67 | 20.02 | 8.98 | ||
34.56 | 1,321 Cr | 50.21 | 2.53 | 0.29 | 6.52 | 6.49 | 3.13 | ||
635.40 | 1,283 Cr | 13.30 | 1.69 | 0.28 | 11.60 | 15.18 | 10.83 | ||
132.20 | 1,218 Cr | 30.47 | 3.33 | 0.38 | 0.42 | 2.70 | 6.68 | ||
| Median: 7 Co. | — | 482.15 | 1,419 Cr | 30.47 | 3.49 | 0.38 | 15.60 | 20.02 | 10.61 |
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
